HMG-CoA reductase inhibitors and bile lithogenicity: cholesterol supersaturation or nucleation defect?
Ahmed
H A
HA
St George's Hospital Medical School, London, UK.
Jazrawi
R P
RP
Northfield
T C
TC
D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology; D001646:Bile / Q000737:chemistry / Q000187:drug effects / Q000502:physiology*; D002769:Cholelithiasis / Q000201:enzymology / Q000209:etiology* / Q000517:prevention & control; D002784:Cholesterol / Q000737:chemistry / Q000502:physiology*; D003460:Crystallization; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
D000924:Anticholesteremic Agents; D004791:Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002784:Cholesterol